Establishment Labs (NASDAQ:ESTA) Stock Price Up 5.4%

Establishment Labs Holdings Inc. (NASDAQ:ESTA) shares rose 5.4% during trading on Tuesday . The stock traded as high as $48.10 and last traded at $47.97. Approximately 63,414 shares changed hands during trading, a decline of 83% from the average daily volume of 374,384 shares. The stock had previously closed at $45.52.

Analyst Upgrades and Downgrades

ESTA has been the topic of several research reports. Mizuho raised their price objective on Establishment Labs from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, June 6th. Citigroup reduced their price objective on Establishment Labs from $60.00 to $50.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.00.

Establishment Labs Trading Up 9.9 %

The stock has a 50-day simple moving average of $48.95 and a 200 day simple moving average of $45.11. The company has a current ratio of 4.24, a quick ratio of 2.73 and a debt-to-equity ratio of 3.38. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -15.37 and a beta of 1.24.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.07. The business had revenue of $37.17 million during the quarter, compared to analysts’ expectations of $35.61 million. Establishment Labs had a negative return on equity of 206.05% and a negative net margin of 53.12%. The company’s revenue for the quarter was down 20.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.48) EPS. As a group, equities research analysts predict that Establishment Labs Holdings Inc. will post -1.79 EPS for the current fiscal year.

Insider Activity at Establishment Labs

In other Establishment Labs news, CEO Quiros Juan Jose Chacon sold 6,839 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $45.30, for a total value of $309,806.70. Following the completion of the sale, the chief executive officer now directly owns 218,896 shares of the company’s stock, valued at approximately $9,915,988.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 14,346 shares of company stock worth $647,806 in the last 90 days. Corporate insiders own 11.44% of the company’s stock.

Hedge Funds Weigh In On Establishment Labs

Several institutional investors and hedge funds have recently bought and sold shares of the company. FNY Investment Advisers LLC purchased a new stake in Establishment Labs during the 4th quarter worth approximately $93,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Establishment Labs by 67.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,591 shares of the company’s stock worth $119,000 after buying an additional 1,845 shares during the period. SG Americas Securities LLC purchased a new stake in Establishment Labs during the 4th quarter worth approximately $120,000. Legato Capital Management LLC increased its stake in Establishment Labs by 63.1% during the 4th quarter. Legato Capital Management LLC now owns 8,438 shares of the company’s stock worth $218,000 after buying an additional 3,263 shares during the period. Finally, Concurrent Investment Advisors LLC purchased a new stake in Establishment Labs during the 1st quarter worth approximately $263,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.